Two masked bispecific antibodies, licensed for $100m, produce promising early data.

The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.

US approval gives Pfizer the first and second-line settings.

Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.

The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.

Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.

The group is persevering with Granite, but funds might be hard to come by.

Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.

So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.